Bristol Myers Squibb Seals the Deal: Mirati Acquisition Strengthens Oncology Portfolio, But What’s the Cost for 2024 Earnings?

Bristol Myers Squibb has successfully concluded its acquisition of cancer drugmaker Mirati Therapeutics, impacting its 2024 adjusted earnings by approximately $0.35 per share, as part of the company's efforts to diversify its oncology portfolio.








